Abstract 69 Figure 1  Overall survival Curve

of optimal cytoreduction (<1 cm largest residual disease) were comparable between groups (79.6% vs 84.1%, p=0.48). The median OS for the whole cohort was 5.9 years. Using Time-varying Cox model, the use of bevacizumab did not improve OS (HR 0.46, 95% CI 0.17–1.25, p=0.13).

Conclusions In our center, the addition of bevacizumab to standard chemotherapy in patients with advanced stage ovarian carcinoma had no impact on OS.

IGCS19-0349

70 IMPACT OF TIMING OF CYTOREDUCTIVE SURGERY(CRS) ON EPITHELIAL OVARIAN CANCER(EOC), PRIMARY PERITONEAL CARCINOMATOSIS(PPC), AND FALLOPIAN TUBE CANCER(FTC) AT AMERICAN UNIVERSITY OF BEIRUT MEDICAL CENTER(AUBMC)

1M Seoud*, 2A El Houssieni, 1J Jaafar, 1K Hamed, 2F Jamal, 3R Abdallah, 1A Khalil, 1American University of Beirut Medical Center, Obstetrics and Gynecology, Beirut, Lebanon; 1American University of Beirut Medical Center, General Surgery, Beirut, Lebanon

10.1136/ijgc-2019-IGCS.70

Objectives To study the impact of timing of CRS weather done at diagnosis or following neoadjuvant chemotherapy (NACT) on progression free(PFS) and overall survival(OS) of patients with advanced EOC between 1997–2017 at AUBMC. Patients underwent either primary debulking (PDS) or received NACT followed by interval debulking surgery (IDS) in cases with extensive disease, multiple comorbidities, or poor performance status.

Methods A retrospective review of the impact of PDS versus NACT followed by IDS on PFS and OS.

Results Of 273 patients with EOC, PPC and FTC, 220 were found to have advanced epithelial cancer (stage IIIB, IIIC and IV). 63% had interval debulking surgery (IDS) while 37% had primary debulking (PDS). Results are shown in table 1. In stage IIIC, the PFS of patients who underwent PDS was significantly higher than patients undergoing IDS (table 1, Pvalue=0.003). In Stage IV, the PFS was not significantly affected by the timing of surgery (table 1, Pvalue=0.274). The OS was not affected by the timing of CRS in all stages.

Conclusions Timing of the CRS (PDS vs. IDS) significantly impacts PFS but not OS in stage IIIC but not IV EOC. This difference in survival is explained by the higher tumor burden, higher morbidity, and worse performance status of patients who underwent IDS.

IGCS19-0133

THE ONCOLOGICAL SAFETY OF HYSTEROSCOPY IN THE DIAGNOSIS OF EARLY-STAGE ENDOMETRIAL CANCER: AN ISRAEL GYNECOLOGIC ONCOLOGY GROUP STUDY

1M Volodarsky*, 2A Namazon, 3O Gemer, 3H helpman, 3H Hag-Yahia, 4R Etlan, 5O Raban, 5Z Vaknin, 5S Leytes, 6O Lavie, 6A Amit, 6T Levy, 10Ben Shachar, 11A Atlas, 12B Bruchim, 13A Ben-Arie. 1Barzilai Medical Center-, Obstetrics-Gynecology Department, Ashkelon, Israel; 2Barzilai University Medical Center- Faculty of Health Science- Ben Gurion University- Ashkelon, Obstetrics-gynecology department, Ashkelon, Israel; 3Med Medical Center- Sackler School of Medicine- Tel Aviv University-, obstetrics-gynecology, Kfar Saba, Israel; 4Rabin Medical Center- Sackler School of Medicine- Tel Aviv University, Obstetrics-gynecology, Petah Tikva, Israel; 5Ashal Harofeh Medical Center- Sackler School of Medicine- Tel Aviv University-, Obstetrics-gynecology, Zrifin, Israel; 6Wolfson Medical Center- Sackler School of Medicine- Tel Aviv University-, Obstetrics-gynecology, Holon, Israel; 7Carmel Medical Center- Rappaport Faculty of Medicine- Technion-, Gynecologic oncology, Haifa, Israel; 8Rambam Medical Center- Rappaport Faculty of Medicine- Technion-, Gynecologic oncology, Haifa, Israel; 9Rabin Medical Center- Sackler School of Medicine- Tel Aviv University-, Gynecologic oncology, Holon, Israel; 10Ziv Medical Center Bar Ilan University-, Obstetrics-gynecology, Zefat, Israel; 11Poriya Medical Center- Bar Ilan University-, obstetrics-gynecology, Tiberia, Israel; 12Hilal Yaffe Medical Center- Rappaport Faculty of Medicine- Technion-, obstetrics-gynecology, Hadera, Israel; 13Kaplan Medical Center- Hebrew University-, Obstetric-gynecology, Rehovot, Israel

10.1136/ijgc-2019-IGCS.71

Objectives To compare survival measures of women with early-stage endometrial cancer who underwent either hysteroscopy or a non-hysteroscopic procedure as a diagnostic procedure.

Methods An Israel Gynecologic Oncology Group multicenter study of 1324 patients with stage I endometrial cancer who underwent surgery between 2002 and 2014. Patients were divided into two groups: hysteroscopy and non-hysteroscopy (curettage or office endometrial biopsy). Clinical, pathological, and survival measures were compared between the groups.

Results There were 335 patients in the hysteroscopy group and 969 patients in the non-hysteroscopy group. The median follow-up was 52 months (range 12–120 months). There were no differences between the groups in the 5-year recurrence-free survival (90.2% vs. 88.2%; p=0.53), disease-specific survival (93.4% vs. 91.7%; p=0.5), and overall survival (86.2% vs. 80.6%; p=0.22).

Abstract 70 Table 1  Effect of timing on the PFS and OS in stages IIIC and IV

<table>
<thead>
<tr>
<th>Stage</th>
<th>Timing</th>
<th>Median PFS (months)</th>
<th>P-value</th>
<th>Median OS (months)</th>
<th>P-value</th>
</tr>
</thead>
<tbody>
<tr>
<td>IIIC</td>
<td>Primary</td>
<td>57</td>
<td>24.0</td>
<td>57</td>
<td>46.0</td>
</tr>
<tr>
<td></td>
<td>Interval</td>
<td>100</td>
<td>20.0</td>
<td>100</td>
<td>48.0</td>
</tr>
<tr>
<td></td>
<td>overall</td>
<td>157</td>
<td>22.0</td>
<td>157</td>
<td>47.0</td>
</tr>
<tr>
<td>IV</td>
<td>Primary</td>
<td>33</td>
<td>14.0</td>
<td>33</td>
<td>28.0</td>
</tr>
<tr>
<td></td>
<td>Interval</td>
<td>14</td>
<td>17.0</td>
<td>14</td>
<td>22.0</td>
</tr>
<tr>
<td></td>
<td>overall</td>
<td>47</td>
<td>15</td>
<td>47</td>
<td>26.0</td>
</tr>
</tbody>
</table>